TOKYO -- Two Japanese medical equipment and pharmaceutical companies are accelerating efforts to put their regenerative medicine businesses to commercial use, as Japan has revised a law to help catch up with the U.S. and Europe in making regenerative medicine products.
A worker at Terumo prepares medical equipment in Kanagawa Prefecture. The company will set up a production system for making cell sheets for cardiac arrest at its research and development center there in the spring.
Terumo will start producing for sale cell sheets for cardiac arrest, called HeartSheet, in April this year. In September 2015 the Tokyo-based medical equipment company received official approval for producing and selling these cell sheets that are made from human cells.
